Agency
The Health Care Authority of the City of Anniston
The Health Care Authority of the City of Anniston was paid $5.61M by Medicaid between Jan 2018 and Nov 2024, across 131 billing codes. Its largest line is 99284, emergency room visit (serious) — 27% of everything it billed.
33Billing provider infoTHE HEALTH CARE AUTHORITY OF THE CITY OF ANNISTON
ANNISTON, AL 36207
ANNISTON, AL 36207
33aNPI1003996000assigned 10/16/2006
33bProvider typeHome Health Agency
28Total paid$5.61M
24GClaims327,997
24DCodes billed131
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Home Health Agency providers in Alabama
Rank by total paid#5 of 68
Median peer was paid$23K
This provider vs. median244×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 41,229 | $519K | |
| 2019 | 46,431 | $637K | |
| 2020 | 33,567 | $455K | |
| 2021 | 41,124 | $603K | |
| 2022 | 57,387 | $1.09M | |
| 2023 | 68,368 | $1.50M | |
| 2024incomplete | 39,891 | $809K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 27% | 25,910 | 23,135 | $1.52M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 28,701 | 25,685 | $1.07M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 7.4% | 2,482 | 2,200 | $416K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.3% | 30,931 | 27,122 | $244K |
| 80053 | Comprehensive metabolic panel | 3.8% | 21,569 | 18,861 | $212K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 3.1% | 7,893 | 6,681 | $176K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.0% | 4,532 | 4,145 | $170K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 2.8% | 36,012 | 27,164 | $159K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.6% | 1,947 | 1,716 | $146K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 2.0% | 7,718 | 6,670 | $114K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.8% | 634 | 481 | $103K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.8% | 10,222 | 8,820 | $100K |
119 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.6% | 3,648 | $88K |
| 87088 | 1.5% | 8,700 | $82K | |
| 87400 | 1.4% | 12,397 | $80K | |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.4% | 3,830 | $78K |
| 81001 | 1.3% | 20,311 | $72K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 1,440 | $60K |
| 99285 | Emergency room visit (most serious) | 1.0% | 248 | $57K |
| 71045 | Radiologic examination, chest; single view | <1% | 11,251 | $53K |
| 83605 | <1% | 6,436 | $50K | |
| 59025 | Fetal non-stress test | <1% | 8,398 | $39K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 331 | $39K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,062 | $35K |
| 87070 | <1% | 2,792 | $31K | |
| 84484 | <1% | 4,259 | $31K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 2,713 | $29K |
| 99223 | Prolong inpt eval add15 m | <1% | 596 | $29K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 987 | $29K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,031 | $22K |
| 87581 | <1% | 635 | $17K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,674 | $16K |
| 81025 | <1% | 4,800 | $15K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 554 | $14K |
| 83690 | <1% | 2,337 | $14K | |
| 87420 | <1% | 921 | $14K | |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 12 | $13K |
| 88304 | <1% | 822 | $12K | |
| 83735 | <1% | 2,049 | $11K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 599 | $9K |
| 82150 | <1% | 1,561 | $8K | |
| 93000 | <1% | 608 | $6K | |
| 85610 | <1% | 1,900 | $6K | |
| 43237 | <1% | 52 | $6K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 25 | $6K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 113 | $6K |
| 83880 | <1% | 266 | $5K | |
| 76377 | <1% | 92 | $5K | |
| 81002 | <1% | 2,262 | $5K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 530 | $5K |
| 87040 | <1% | 611 | $5K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 681 | $4K |
| 43259 | <1% | 27 | $4K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 121 | $4K |
| D9420 | <1% | 13 | $4K | |
| 80076 | <1% | 947 | $4K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 294 | $3K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,721 | $3K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 802 | $3K |
| 43249 | <1% | 39 | $3K | |
| 85730 | <1% | 1,699 | $3K | |
| 82550 | <1% | 441 | $3K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 17 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,148 | $3K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,854 | $3K |
| 84702 | <1% | 229 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,861 | $2K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 95 | $2K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 105 | $2K |
| 78227 | <1% | 12 | $2K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 95 | $2K |
| 76801 | <1% | 74 | $2K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 15 | $2K |
| 84550 | <1% | 218 | $1K | |
| 95819 | <1% | 100 | $1K | |
| 87077 | <1% | 2,626 | $1K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 25 | $1K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 92 | $1K |
| 83615 | <1% | 175 | $1K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 149 | $1K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 15 | $897.92 |
| 81000 | <1% | 434 | $844.95 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 61 | $770.00 |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 65 | $665.14 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 924 | $655.57 |
| 82140 | <1% | 66 | $566.94 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 63 | $552.68 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,120 | $550.88 |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 49 | $537.60 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 288 | $530.86 |
| 87186 | <1% | 79 | $500.70 | |
| 87280 | <1% | 26 | $417.04 | |
| 85379 | <1% | 47 | $359.36 | |
| 84439 | <1% | 74 | $343.06 | |
| 93018 | <1% | 79 | $297.67 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 13 | $287.36 |
| 86900 | <1% | 159 | $256.34 | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 12 | $245.00 |
| 86901 | <1% | 142 | $237.70 | |
| 82565 | <1% | 29 | $177.40 | |
| 86850 | <1% | 69 | $175.71 | |
| 93016 | <1% | 43 | $153.86 | |
| 80061 | Lipid panel | <1% | 38 | $109.60 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 203 | $105.12 |
| 84156 | <1% | 16 | $53.88 | |
| 85027 | <1% | 52 | $51.56 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 13 | $40.08 |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,932 | $23.77 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 24 | $14.88 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 194 | $6.77 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,921 | $0.03 |
| 1160F | 0% | 166 | $0.00 | |
| 3288F | 0% | 149 | $0.00 | |
| 1159F | 0% | 166 | $0.00 | |
| 3078F | 0% | 103 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 16 | $0.00 |
| 3077F | 0% | 15 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 14 | $0.00 |
| 99152 | 0% | 32 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 16 | $0.00 |
| 1126F | 0% | 263 | $0.00 | |
| 82962 | 0% | 157 | $0.00 | |
| 3074F | 0% | 70 | $0.00 | |
| 3008F | 0% | 151 | $0.00 | |
| 1036F | 0% | 87 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 60 | $0.00 |
| 0012A | 0% | 45 | $0.00 | |
| 80320 | 0% | 59 | $0.00 | |
| J3490 | Unclassified drugs | 0% | 35 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 13 | $0.00 |
| 0011A | 0% | 51 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBASS, LOUIS (CEO)
| Provider | Location | Paid |
|---|---|---|
| Regional Health Management Corporation | Anniston, AL | $1.57M |
| The Health Care Authority of the City of Anniston | Anniston, AL | $1.02M |
| The Health Care Authority of the City of Anniston | Jacksonville, AL | $73K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.